menu
    • menu
    [{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"LG Chem","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"TT-01025","moa":"VAP-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"TransThera Biosciences","amount2":0.34999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0.34999999999999998,"dosageForm":"Oral","sponsorNew":"TransThera Biosciences \/ LG Chem Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"TransThera Biosciences \/ LG Chem Life Sciences"},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Teijin Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"TransThera Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TransThera Biosciences \/ TransThera Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"TransThera Biosciences \/ TransThera Biosciences"},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"TT-00420","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TransThera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TransThera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TransThera Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"TT-02332","moa":"","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"TransThera Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"TransThera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TransThera Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"TT-00420","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"TransThera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TransThera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TransThera Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"TT-00420","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"TransThera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TransThera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TransThera Biosciences \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by TransThera Biosciences

    Menu

    TransThera Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TransThera Biosciences

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            TransThera Biosciences

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TT-00420

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TransThera Announces Global Phase 3 Trial for Cholangiocarcinoma and ODD

                            Details : TT-00420 (Tinengotinib), a next-generation FGFR inhibitor with, showning promising clinical benefit in subjects with FGFR-altered metastatic CCA.

                            Brand Name : TT-00420

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 08, 2024

                            Lead Product(s) : TT-00420

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TransThera Biosciences

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            TransThera Biosciences

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TT-02332

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TransThera Starts IND Studies for TT-02332, a Potent CNS-Penetrating NLRP3 Inhibitor

                            Details : TT-02332 is a novel, highly potent and CNS-penetrating NLRP3 inhibitor. It is being evaluated for the treatment of obesity, inflammatory bowel disease & dermatitis.

                            Brand Name : TT-02332

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 26, 2024

                            Lead Product(s) : TT-02332

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            TransThera Biosciences

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            TransThera Biosciences

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TT-00420

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TransThera Announces the Global Multicenter Phase 3 Clinical Trial Completed First Patient Dosing in the US Ev...

                            Details : TT-00420 (tinengotinib), which is an investigational next-generation FGFR inhibitor. currently, it is being evaluated in the Phase III clinical trial studies with patients for the treatment of advanced FGFR-altered cholangiocarcinoma.

                            Brand Name : TT-00420

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 21, 2023

                            Lead Product(s) : TT-00420

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            TransThera Biosciences

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            TransThera Biosciences

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TT-00420

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TransThera Receives Fast Track Designation from FDA for its Core Product TT-00420 to Treat Cholangiocarcinoma

                            Details : TT-00420 is spectrum selective kinase inhibitor that is found to show high potency to a variety of clinically identified FGFR2 mutations in preclinical experiments. A large number of preclinical studies have found that TT-00420 has promising inhibitory e...

                            Brand Name : TT-00420

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 03, 2021

                            Lead Product(s) : TT-00420

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            TransThera Biosciences

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            TransThera Biosciences

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Teijin Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Teijin Pharma and TransThera Biosciences Form Strategic R&D Collaboration

                            Details : Teijin Pharma and TransThera will establish a joint drug discovery collaboration of multiple drug targets with the immediate goal of acquiring compounds as candidates for new drug development based on the targets and compounds found by Teijin Pharma.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 18, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Teijin Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            TransThera Biosciences

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            TransThera Biosciences

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TT-01025

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Preclinical

                            Sponsor : LG Chem

                            Deal Size : $350.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            LG Chem Life Sciences and TransThera Biosciences Ink License Agreement for Treatment of NASH

                            Details : Under the terms of the agreement, LG Chem will obtain exclusive worldwide rights, except Greater China region and Japan, to develop and commercialize TT-01025.

                            Brand Name : TT-01025

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 18, 2020

                            Lead Product(s) : TT-01025

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Preclinical

                            Sponsor : LG Chem

                            Deal Size : $350.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth